BNR

Burning Rock Biotech

13.20 USD
--0.26
1.93%
At close Updated Nov 3, 11:38 AM EST
1 day
-1.93%
5 days
8.2%
1 month
46.34%
3 months
114.63%
6 months
445.45%
Year to date
78.62%
1 year
387.08%
5 years
-95.05%
10 years
-94.64%
 

About: Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Employees: 674

0
Funds holding %
of 7,505 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™